Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group | Health & Environmental Research Online (HERO)

Health & Environmental Research Online (HERO)

Print Feedback Export to File

This record has one attached file:

Citation
Tags

HERO ID

7023195

Reference Type

Journal Article

Title

Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group

Author(s)

Ettrich, TJ; Berger, AW; Perkhofer, L; Daum, S; König, A; Dickhut, A; Wittel, U; Wille, K; Geissler, M; Algül, H; Gallmeier, E; Atzpodien, J; Kornmann, M; Muche, R; Prasnikar, N; Tannapfel, A; Reinacher-Schick, A; Uhl, W; Seufferlein, T; ,

Year

2018

Is Peer Reviewed?

Yes

Journal

BMC Cancer
ISSN: 1471-2407
EISSN: 14712407

Publisher

BMC

Location

LONDON

Language

English

PMID

30594153

DOI

10.1186/s12885-018-5183-y

Web of Science Id

WOS:000454559600002

Abstract

Even clearly resectable pancreatic cancer still has an unfavorable prognosis. Neoadjuvant or perioperative therapies might improve the prognosis of these patients. Thus, evaluation of perioperative chemotherapy in resectable pancreatic cancer in a prospective, randomized trial is warranted. A substantial improvement in overall survival of patients with metastatic pancreatic cancer with FOLFIRINOX and nab-paclitaxel/gemcitabine vs standard gemcitabine has been demonstrated in phase III-trials. Indeed nab-paclitaxel/gemcitabine has a more favorable toxicity profile compared to the FOLFIRINOX protocol and appears applicable in a perioperative setting.